Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine



Rating:

Share or cite this content

Citations should be made in the following way:
David Planchard (France). Therapeutic strategy for other oncogenic drivers. New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

Member's Comments

No comment yet.

Related content which might interest you: Therapeutic strategy for ALK/ROS driven NSCLC Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Therapeutic strategy for EGFR driven NSCLC Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Targeting metabolic reprogramming as a novel anti-fibrotic strategy Source: International Congress 2019 – Metabolic alterations as a driver of chronicity in lung disease Year: 2019 How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021 Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities Source: Eur Respir J 2014; 44: 513-522 Year: 2014 Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma Source: Eur Respir J, 53 (2) 1802444; 10.1183/13993003.02444-2018 Year: 2019 What are the main mechanisms of oncogenic addiction? Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Failure of EGFR TKI treatment: mechanisms and current strategies? Source: ERS Research Seminar Year: 2015 Novel targets and emerging therapies in MPM Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 Potential of regulatory T-cell-based therapies in the management of severe COVID-19 Source: Eur Respir J, 56 (3) 2002182; 10.1183/13993003.02182-2020 Year: 2020 Practical considerations for therapies targeting the prostacyclin pathway Source: Eur Respir Rev 2016; 25: 418-430 Year: 2016 Therapeutic strategies: what treatment for what patient Source: Annual Congress 2008 - PG12 - Challenges in pulmonary embolism: hot issues and interactive cases (jointly organised with ACCP) Year: 2008 Targeting the arginase pathway: potential developments as new avenues for treatment Source: Annual Congress 2004 - Arginase: a novel target and marker for asthma? Year: 2004 Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008 Therapeutic implications Source: Annual Congress 2009 - The lung cancer-COPD nexus Year: 2009 Therapeutic approaches to lung aging Source: International Congress 2016 – The future is now: the challenge of ageing in respiratory medicine Year: 2016 Late Breaking Abstract - Anaplastic Lymphoma Kinase inhibition as an effective treatment strategy against the enhanced lung carcinogenesis and cancer angiogenesis related to decreased PTPRZ1 expression Source: Virtual Congress 2020 – Biological aspects of lung cancer Year: 2020 Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19 Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020 Year: 2020